Cancer genomes let drugmakers get personal
from Technology Review
A growing effort to personalize cancer medicine tries to link existing drugs to patients based on the specific genetic and molecular anomalies of a patient's cancer. But H3 Biomedicines, a startup in Cambridge, Mass., wants to personalize cancer drugs from the beginning by designing drugs to target specific patient populations.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063